Skip to main content

CTOS 2023 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Dorit Di Gioia, MD

Department of Medicine III, LMU University Hospital, LMU Munich, Germany

Poster(s):

(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS